Review of Outcome Measures in Trials and Practice for Psoriasis
- 9 Downloads
Purpose of Review
The purpose of this review was to determine the most frequently utilized outcome measures in clinical trials and to review the scoring criteria, advantages, disadvantages, and application in research and clinical settings, as well as provide an overview of the published guidelines on the use of outcome measures in clinical practice.
The most frequently utilized physician-reported outcome measurement instruments in clinical trials from 2018 to 2019 were Physician Global Assessment (PGA), Psoriasis Area Severity Index (PASI), and body surface area. The most frequently utilized patient-reported outcome measurement instruments were Dermatology Quality of Life Index, EQ-5D-5L, and patient global assessment.
In research, further standardization of outcome measures may allow for more useful comparison of different treatment modalities. In clinical practice, although, the PASI provides a detailed measurement of disease severity, and the PGA score has the advantage of being more clinically useful to physicians and patients.
KeywordsPsoriasis Outcome measures Psoriasis area severity index Physician’s global assessment National Psoriasis Foundation Dermatology quality life index
Compliance with Ethical Standards
Conflict of Interest
Steven Feldman has received research, speaking, and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.
Payvand Kamrani and Arjun Bashyam have no conflicts to disclose.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies. Clin Dermatol. 2010;28(1):67–72. https://doi.org/10.1016/j.clindermatol.2009.03.001.PubMedGoogle Scholar
- 6.Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol. 2006;155(4):707–13.PubMedGoogle Scholar
- 11.Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23–31.Google Scholar
- 13.Feldman S. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat. 2004;15(1):27–9.Google Scholar
- 14.Po LW. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185–91.Google Scholar
- 17.• Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8 This is a consensus paper that provides guidelines on what outcome measurements to use endrosed by the National Psoriasis Foundation. This is important as it is a well-known professional soceity offereing guidance on this topic. PubMedGoogle Scholar
- 19.• Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJ, Bertheussen H, et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheum. 2018;70(3):345–55 This paper provided consenses from GRAPPA’s meeting to disucss recommendations for use of measurements and treatment targets. This is important as it provides additional guidelines for which outcome measurements to use. Google Scholar
- 23.• Wechter T, Heath M, Aung-Din D, Sahni D, Cline A, Feldman SR. Current psoriasis efficacy outcome measures in clinical trials. Curr Dermatol Rep. 2018;7(4):261–8 This paper is a review paper in which studied the outcome measurements from 2017–2018. The methods was very similar to the methods used for this paper; however, we incorportated clinical practice guidelines and reviewed measurements for 2018–2019. Google Scholar